Von Hippel-Lindau disease OMIM 193300

In Von Hippel-Lindau disease OMIM 193300 (VHL, OMIM 193300), the master switch sits on the ↑ UP branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: clear). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.

The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.5130, γ 1.4325, spinodal 0.6599). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.

The emergence switch

The switch for Von Hippel-Lindau disease OMIM 193300 is an R19 double-well emerged from the real proximal-promoter DNA of VHL. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.

emergent axis
↑ UP [F]
healthy branch
ON
lesion
LOF_null
γ (stiffness)
1.4325
barrier
0.5130
spinodal
0.6599
s_on / s_off
1.1969 / -1.1969
fragility
0.39
corrective polarity
clear
forced direction
raise s toward ON branch

Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically harder (barrier 0.513 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.

The derived corrective lever

The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).

h-restore (drive modulator)sign: decreasegeometric rank 0.39
Mechanism. remove / oppose the drive (clear the accumulating load that pins the disease branch)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If clearing/opposing the accumulating EPAS1 does NOT relieve the disease branch in a VHL model, the h-restore(clear) lever is refuted for this axis.
gamma-restore (stabiliser / chaperone)sign: Nonegeometric rank 0.00
Mechanism. N/A
Applies to. none (honest exclusion)
EXCLUDED: null allele -- no product to stiffen
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual VHL allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.

Agents mapped onto the lever

✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: HIF-2alpha inhibitor (belzutifan). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)dir.statusphasemap
HIF-2alpha inhibitor (belzutifan)
Jonasch 2021 NEJM 385:2036 (belzutifan in VHL-associated tumours); Choueiri 2021 Nat Med 27:802 (belzutifan ccRCC); belzutifan (Welireg) FDA 2021
decreaseapproved4✓ in use
VHL gene / function restoration (investigational)
Maxwell 1999 Nature 399:271 (pVHL HIF-degradation function as the restoration target); investigational, no approved VHL gene therapy
decreaseinvestigational2◇ in trials
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Direction-only candidate leads (corpus join)

Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.

belzutifan✓ recovered standarddir: decrease · approved
Class. HIF-2-alpha inhibitor (downstream drive suppressor)
Mechanism. When VHL is lost, hypoxia-inducible factor 2-alpha is not degraded and constitutively drives its target programme; belzutifan blocks HIF-2-alpha, lowering that downstream drive. Direction: decrease / clear the accumulated HIF-2-alpha signalling. Allele scope: agnostic -- a downstream pathway block independent of the VHL variant. Pathway-specific (mapped to VHL disease via VHL only). The decrease direction recovers an approved VHL-tumour indication.
✓ This is a rediscovery. Belzutifan (HIF-2-alpha inhibitor) is approved for VHL-associated tumours (lowering the downstream HIF drive); the direction logic recovered an approved indication.
Safety (qualitative; no magnitude). anaemia and hypoxia monitoring on label (qualitative; no magnitude)
Falsifier. If belzutifan (a pathway decrease agent) clearing/opposing the accumulating load does NOT relieve the UP [F] disease branch in a VHL model, the h-restore(clear) direction is refuted for belzutifan here.
Source: FDA/EMA label: belzutifan (Welireg), VHL; Jonasch 2021 NEJM 385:2036
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Evidence & provenance

What is reproduced vs. cited for this page.
elementgradebasis
R19 switch & cusp geometry (this page)[V] verifiedemerged from measured promoter γ of VHL; deterministic, 2×sha256 identical
corrective direction[F] forcedforced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads[O] opendirection-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude

Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).